Compare · BBNX vs DXCM
BBNX vs DXCM
Side-by-side comparison of Beta Bionics Inc. (BBNX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.50B, about 35.5x BBNX ($888.1M).
- Over the past year, BBNX is down 18.1% and DXCM is up 29.8% - DXCM leads by 47.8 points.
- BBNX has been more active in the news (10 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 21 for BBNX).
- Company
- Beta Bionics Inc.
- DexCom Inc.
- Price
- $16.89-2.62%
- $86.01-1.97%
- Market cap
- $888.1M
- $31.50B
- 1M return
- -21.09%
- -2.07%
- 1Y return
- -18.07%
- +29.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2005
- News (4w)
- 10
- 6
- Recent ratings
- 21
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BBNX
- BBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action Deadline
- Jefferies initiated coverage on Beta Bionics with a new price target
- BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
- SEC Form SCHEDULE 13G filed by Beta Bionics Inc.
- Barclays initiated coverage on Beta Bionics with a new price target
- SEC Form 4 filed by Beta Bionics Inc.
- Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Director Jones Christy sold $147,890 worth of shares (6,430 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 19,564 units (SEC Form 4)
- Wells Fargo initiated coverage on Beta Bionics with a new price target
- Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer